GURUFOCUS.COM » STOCK LIST » USA » NAS » OncoCyte Corp (NAS:OCX) » Definitions » 3-Year Book Growth Rate
Switch to:

OncoCyte (NAS:OCX) 3-Year Book Growth Rate

: 103.40% (As of Sep. 2022)
View and export this data going back to 2015. Start your Free Trial

OncoCyte's Book Value per Share for the quarter that ended in Sep. 2022 was $0.65.

During the past 12 months, OncoCyte's average Book Value per Share Growth Rate was -39.90% per year. During the past 3 years, the average Book Value per Share Growth Rate was 103.40% per year. During the past 5 years, the average Book Value per Share Growth Rate was 30.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 9 years, the highest 3-Year average Book Value per Share Growth Rate of OncoCyte was 103.40% per year. The lowest was -41.00% per year. And the median was 16.40% per year.


Competitive Comparison

For the Biotechnology subindustry, OncoCyte's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

OncoCyte 3-Year Book Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where OncoCyte's 3-Year Book Growth Rate falls in comparison to its industry or sector. The grey bar indicates the 3-Year Book Growth Rate's extreme value range as defined by GuruFocus.



OncoCyte 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.


OncoCyte  (NAS:OCX) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.


OncoCyte 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of OncoCyte's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (NAS:OCX) Business Description

OncoCyte logo
Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Executives
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund director C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Gisela Paulsen officer: Chief Operating Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas T. Ross officer: Chief Medical Officer 15 CUSHING, IRVINE CA 92618
Tony T Kalajian officer: SVP-Chief Accounting Officer 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Padma Sundar officer: SVP, Marketing & Market Access 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008

OncoCyte (NAS:OCX) Headlines

Other Sources

OncoCyte (OCX) Gets a Buy from Needham

By tipranks.com 2022-11-11